(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
The Sickle Cell and Hemoglobin program is home to specialists with a wide variety of backgrounds and areas of focus. As a team, this diversity makes us better prepared to care for your child’s unique needs. Learn more about our faculty and staff.
Punam Malik, MD Marjory J. Johnson Chair of Gene and Cell Therapy 513-636-1333 email@example.com
Marjory J. Johnson Chair of Gene and Cell Therapy
Director, Comprehensive Sickle Cell Program
Program Leader, Hematology and Gene Therapy Program
Professor, UC Department of Pediatrics
MBBS: University of Delhi, New Delhi, India, 1985.
MD: University of Delhi, New Delhi, India, 1989.
MS: University of Maryland, Baltimore, MD, 1991.
Fellowship: Children's Hospital Los Angeles, University of Southern California, 1995.
Arumugam P, Malik P. Genetic therapy for beta-thalassemia: from the bench to the bedside. Hematology Am Soc Hematol Educ Program. 2010;2010:445-50.
Perumbeti A, Malik P. Therapy for beta-globinopathies: a brief review and determinants for successful and safe correction. Ann N Y Acad Sci. 2010 Aug;1202:36-44. Review.
Perumbeti A, Malik P. Genetic correction of sickle cell anemia and beta-thalassemia: progress and new perspective. Scientific World Journal. 2010 Apr 13;10:644-54. Review.
Sundaram N, Tailor A, Mendelsohn L, Wansapura J, Wang X, Higashimoto T, Pauciulo MW, Gottliebson W, Kalra VK, Nichols WC, Kato GJ, Malik P. High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. Blood. 2010 Jul 8;116(1):109-12.
Wang D, Zhang W, Kalfa TA, Grabowski G, Davies S, Malik P, Pan D. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19958-63.
Arumugam PI, Urbinati F, Velu CS, Higashimoto T, Grimes HL, Malik P. The 3' region of the chicken hypersensitive site-4 insulator has properties similar to its core and is required for full insulator activity. PLoS One. 2009 Sep 10;4(9):e6995.
Arumugam PI, Higashimoto T, Urbinati F, Modlich U, Nestheide S, Xia P, Fox C, Corsinotti A, Baum C, Malik P. Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region. Mol Ther. 2009 Nov;17(11):1929-37.
Perumbeti A, Higashimoto T, Urbinati F, Franco R, Meiselman HJ, Witte D, Malik P. A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. Blood. 2009 Aug 6;114(6):1174-85.
Urbinati F, Arumugam P, Higashimoto T, Perumbeti A, Mitts K, Xia P, Malik P. Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3'LTR. Mol Ther. 2009 Sep;17(9):1527-36.
Williams JP, Wu J, Johansson G, Rizvi TA, Miller SC, Geiger H, Malik P, Li W, Mukouyama YS, Cancelas JA, Ratner N. Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential. Cell Stem Cell. 2008 Dec 4;3(6):658-69.
Karen A. Kalinyak, MD Medical Director, Sickle Cell Clinic 513-636-4266 firstname.lastname@example.org
Medical Director, Sickle Cell Clinic
Hematology; bone marrow failure; sickle cell anemia; hemoglobinopathy
MD: Temple University, Philadelphia, PA, 1977.
Residency: Children's Hospital Medical Center, Cincinnati, OH, 1980.
Fellowship: Children's Hospital Medical Center, Cincinnati, OH, 1983.
Certification: Pediatrics, 1984; Pediatric Hematology/Oncology, 1987.
King AA, Rodeghier MJ, Panepinto JA, Strouse JJ, Casella JF, Quinn CT,
Dowling MM, Sarnaik SA, Thompson AA, Woods GM, Minniti CP,
Redding-Lallinger RC, Kirby-Allen M, Kirkham FJ, McKinstry R, Noetzel
MJ, White DA, Kwiatkowski JK, Howard TH, Kalinyak KA, Inusa B, Rhodes
MM, Heiny ME, Fuh B, Fixler JM, Gordon MO, DeBaun MR. Silent cerebral infarction, income, and grade retention among students with sickle cell anemia. Am J Hematol. 2014 Oct;89(10):E188-92.
DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, Meier ER, Howard TH, Majumdar S, Inusa BP, Telfer PT, Kirby-Allen M, McCavit TL, Kamdem A, Airewele G, Woods GM, Berman B, Panepinto JA, Fuh BR, Kwiatkowski JL, King AA, Fixler JM, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Dixon N, Gonzalez CE, Kalinyak KA, Quinn CT, Strouse JJ, Miller JP, Lehmann H, Kraut MA, Ball WS Jr, Hirtz D, Casella JF. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014 Aug 21; 371(8):699-710.
Crosby LE, Barach I, McGrady ME, Kalinyak KA, Eastin AR, Mitchell MJ. Integrating interactive web-based technology to assess adherence and clinical outcomes in pediatric sickle cell disease. Anemia. 2012;2012:492428.
Debaun MR, Sarnaik SA, Rodeghier MJ, Minniti CP, Howard TH, Iyer RV, Inusa B, Telfer PT, Kirby-Allen M, Quinn CT, Bernaudin F, Airewele G, Woods GM, Panepinto JA, Fuh B, Kwiatkowski JK, King AA, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Sabio H, Gonzalez CE, Saccente SL, Kalinyak KA, Strouse JJ, Fixler JM, Gordon MO, Miller JP, Ichord RN, Casella JF. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, gender and relative high systolic blood pressure. Blood. 2012 Apr;119(16):3684-90.
McCarville MB, Rogers ZR, Sarnaik S, Scott P, Aygun B, Hilliard L, Lee MT, Kalinyak K, Owen W, Garro J, Schultz W, Yovetich N, Ware RE, SWiTCH Investigators. Effects of Chronic Transfusions on Abdominal Sonographic Abnormalities in Children with Sickle Cell Anemia. J Pediatr. 2012 Feb;160(2):281-285.
Kwiatkowski JL, Yim E, Miller S, Adams RJ, STOP 2 Study Investigators. Effect of transfusion therapy on transcranial Doppler ultrasonography velocities in children with sickle cell disease. Pediatr Blood Cancer. 2011 May;56(5):777-82.
George A, Benton J, Pratt J, Kim MO, Kalinyak KA, Kalfa TA, Joiner CH. The impact of the 2009 H1N1 influenza pandemic on pediatric patients with sickle cell disease. Pediatr Blood Cancer. 2011 Feb.
Wang W, Brugnara C, Snyder C, Wynn L, Rogers Z, Kalinyak K, Brown C, Qureshi A, Bigelow C, Neumayr L, Smith-Whitley K, Chui DH, Delahunty M, Woolson R, Steinberg M, Telen M, Kesler K. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. Br J Haematol. 2011 Jan;1365-2141.
Mizukawa B, George A, Pushkaran S, Weckbach L, Kalinyak K, Heubi JE, Kalfa TA. Cooperating G6PD mutations associated with severe neonatal hyperbilirubinemia and cholestasis. Pediatr Blood Cancer. 2011 May;56(5):840-2.
Dampier C, Lieff S, LeBeau P, Rhee S, McMurray M, Rogers Z, Smith-Whitley K, Wang W, Comprehensive Sickle Cell Centers Clinical Trial Consortium. Health-related quality of life in children with sickle cell disease: a report from the Comprehensive Sickle Cell Center Clinical Trial Consortium (CTC). Pediatr Blood Cancer. 2010 Sep;55(3):485-94.
Theodosia A. Kalfa, MD, PhD 513-636-0989 email@example.com
Associate Professor, UC Department of Pediatrics
Signaling in erythrocytes; erythropoiesis; sickle cell disease; reactive oxygen species
Visit the Kalfa Lab.
MD: Aristotle University Medical School, Thessaloniki, Greece, 1990.
PhD: Aristotle University Medical School, Thessaloniki, Greece, 1997.
Residency: University Of North Carolina, Chapel Hill, NC, 1999.
Fellowship: Duke University Medical Center, Durham, NC, 2003.
Certification: Hematology / oncology, American Board of Pediatrics, 2004; Pediatrics, American Board of Pediatrics, 2000; ECFMG Certification, 1995.
Licenses: Full and unrestricted medical license (OH Medical Board), 2003-present; full and unrestricted license of medical practice in Greece, 1990-present.
George A, Pushkaran S, Konstantinidis DG, Koochaki S, Malik P, Mohandas N, Zheng Y, Joiner CH, Kalfa TA. Erythrocyte NADPH oxidase activity modulated by Rac GTPases, PKC, and plasma cytokines contributes to oxidative stress in sickle cell disease. Blood. 2013 Mar 14;121(11):2099-107.
Konstantinidis DG, Pushkaran S, Johnson JF, Cancelas JA, Manganaris S, Harris CE, Williams DA, Zheng Y, Kalfa TA. Signaling and cytoskeletal requirements in erythroblast enucleation. Blood. 2012 Jun 21;119(25):6118-27.
Hammill AM, Risinger MA, Joiner CH, Keddache M, Kalfa TA. Compound heterozygosity for two novel mutations in the erythrocyte protein 4.2 gene causing spherocytosis in a Caucasian patient. Br J Haematol. 2011 Jan 31.
Kalfa TA. Anchoring at an island to relieve stress. Blood. 2011 Jan 20;117(3):748-9.
Mizukawa B, George A, Pushkaran S, Weckbach L, Kalinyak K, Heubi JE, Kalfa TA. Cooperating G6PD mutations associated with severe neonatal hyperbilirubinemia and cholestasis. Pediatr Blood Cancer. 2010 Oct 14.
Konstantinidis DG, George A, Kalfa TA. Rac GTPases in erythroid biology. Transfus Clin Biol. 2010 Sep;17(3):126-30.
Kalfa TA, Pushkaran S, Zhang X, Johnson JF, Pan D, Daria D, Geiger H, Cancelas JA, Williams DA, Zheng Y. Rac1 and Rac2 GTPases are necessary for early erythropoietic expansion in the bone marrow but not in the spleen. Haematologica. 2010 Jan;95(1):27-35.
Mulloy JC, Cancelas JA, Filippi MD, Kalfa TA, Guo F, Zheng Y. Rho GTPases in hematopoiesis and hemopathies. Blood. 2010 Feb 4;115(5):936-47.
Daria D, Filippi MD, Knudsen ES, Faccio R, Li Z, Kalfa T, Geiger H. The retinoblastoma tumor suppressor is a critical intrinsic regulator for hematopoietic stem and progenitor cells under stress. Blood. 2008 Feb 15;111(4):1894-902.
Rho GTPases in Terminal Erythroid Maturation. Principal Investigator. NIH/NHLBI. Sep 2012-Jun 2016. #1R01HL116352.
Cincinnati Center of Excellence in Hemoglobinopathies Research. Co-investigator. NIH/NHLBI. Aug 2013–May 2018. # U01 HL117709.
Charles T. Quinn, MD, MS Director, Hematology Clinical and Translational Research 513-636-4266 firstname.lastname@example.org
Director, Hematology Clinical and Translational Research
Director, Hemoglobinopathy Laboratory
Sickle cell disease; thalassemia; hemoglobinopathies; anemia; autoimmune hemolytic anemia; disorders of red blood cells; iron overload and iron chelation; chronic transfusion therapy; immune thrombocytopenia (ITP); neutropenia; stroke
Epidemiology, pathophysiology, treatment and prevention of brain injury (structural and cognitive) in sickle cell disease; measurement of red blood cell turnover in sickle cell disease; identification and treatment of cardiomyopathy and nephropathy in sickle cell disease; treatment and prevention of pain (VOC) in sickle cell disease; MRI methods of iron quantitation; new agents for immune thrombocytopenia (ITP)
Dr. Quinn’s main interests and expertise are in patient-oriented and translational research in sickle cell disease and thalassemia. His formal clinical and translational research training has included: (1) the NIH-K30 Curriculum in Patient-Oriented Research; (2) the Clinical Research Training Institute of the American Society of Hematology; (3) the NIH-K12/KL2 Clinical Scholars Program; and (4) a master’s degree in clinical sciences. Dr. Quinn is a member of the Editorial Board for Pediatric Blood and Cancer and the Board of Contributing Editors for The Hematologist. Dr. Quinn is on the Medical Advisory Board for the Cooley’s Anemia Foundation, and he is a member of the Committee on Educational Affairs of the American Society of Hematology. Locally, he is the medical director of the Ohio Department of Health Regional Sickle Cell Services Program – Region 1.
MD: University of Texas Southwestern Medical Center, Dallas, TX, 1994.
MS: University of Texas Southwestern Medical Center, Dallas, TX, 2008.
Residency & Chief Residency: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 1998.
Fellowship: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 2001.
Certifications: Pediatrics, 1998; Pediatric Hematology-Oncology, 2002.
DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, Meier ER, Howard TH, Majumdar S, Inusa BP, Telfer PT, Kirby-Allen M, McCavit TL, Kamdem A, Airewele G, Woods GM, Berman B, Panepinto JA, Fuh BR, Kwiatkowski JL, King AA, Fixler JM, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Dixon N, Gonzalez CE, Kalinyak KA, Quinn CT, Strouse JJ, Miller JP, Lehmann H, Kraut MA, Ball WS Jr, Hirtz D, Casella JF. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014 Aug 21;371(8):699-710.
King AA, Rodeghier MJ, Panepinto JA, Strouse JJ, Casella JF, Quinn CT, Dowling MM, Sarnaik SA, Thompson AA, Woods GM, Minniti CP, Redding-Lallinger RC, Kirby-Allen M, Kirkham FJ, McKinstry R, Noetzel MJ, White DA, Kwiatkowski JK, Howard TH, Kalinyak KA, Inusa B, Rhodes MM, Heiny ME, Fuh B, Fixler JM, Gordon MO, DeBaun MR. Silent cerebral infarction, income, and grade retention among students with sickle cell anemia. Am J Hematol. 2014 Jul 15.
Vetter CL, Buchanan GR, Quinn CT. Burden of diagnostic radiation exposure in children with sickle cell disease. Pediatr Blood Cancer. 2014 Jul;61(7):1322-4.
Dowling MM, Noetzel MJ, Rodeghier MJ, Quinn CT, Hirtz DG, Ichord RN, Kwiatkowski JL, Roach ES, Kirkham FJ, Casella JF, DeBaun MR. Headache and migraine in children with sickle cell disease are associated with lower hemoglobin and higher pain event rates but not silent cerebral infarction. J Pediatr. 2014 May;164(5):1175-1180.e1.
Chandrakasan S, Bakeer N, Mo JQ, Cost C, Quinn CT. Iron-refractory microcytic anemia as the presenting feature of unicentric Castleman disease in children. J Pediatr. 2014 Apr;164(4):928-30.
King AA, Strouse JJ, Rodeghier MJ, Compas BE, Casella JF, McKinstry RC, Noetzel MJ, Quinn CT, Ichord R, Dowling MM, Miller JP, Debaun MR. Parent education and biologic factors influence on cognition in sickle cell anemia. Am J Hematol. 2014 Feb;89(2):162-7.
Quinn CT. Sickle cell disease in childhood: from newborn screening through transition to adult medical care. Pediatr Clin North Am. 2013 Dec;60(6):1363-81.
McCavit TL, Xuan L, Zhang S, Flores G, Quinn CT. National trends in incidence rates of hospitalization for stroke in children with sickle cell disease. Pediatr Blood Cancer. 2013 May;60(5):823-7.
Quinn CT, McKinstry RC, Dowling MM, Ball WS, Kraut MA, Casella JF, Dlamini N, Ichord RN, Jordan LC, Kirkham FJ, Noetzel MJ, Roach ES, Strouse JJ, Kwiatkowski JL, Hirtz D, DeBaun MR. Acute silent cerebral ischemic events in children with sickle cell anemia. JAMA Neurol. 2013 Jan;70(1):58-65.
Trachtenberg FL, Mednick L, Kwiatkowski JL, Neufeld EJ, Haines D, Pakbaz Z, Thompson AA, Quinn CT, Grady R, Sobota A, Olivieri N, Horne R, Yamashita R. Thalassemia Clinical Research Network. Beliefs about chelation among thalassemia patients. Health Qual Life Outcomes. 2012 Dec 7;10:148.
A feasibility study of regadenoson for the treatment of acute chest syndrome. Co-investigator. National Institutes of Health. April 2012-March 2017. P50HL110790.
Cincinnati Center of Excellence in Hemoglobinopathies Research. Co-PI. National Institutes of Health. Aug 2013–May 2018. U01 HL117709.
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease. Co-Investigator. Eli Lilly and Co. Jan 2013–Dec 2015.
Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trail of ANX-188 (Purified Poloxamer 188) Injection in Children with Sickle Cell Disease Experiencing Vaso-Occlusive Crisis. Co-Investigator. MAST Therapeutics. Nov 2012–Dec 2015.
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects. Co-Investigator. Amgen Inc. Oct 2013–Dec 2015.
Lori E. Crosby, PsyD Pediatric Psychologist, Research, Behavioral Medicine & Clinical Psychology 513-636-4336 email@example.com
Pediatric Psychologist, Research, Behavioral Medicine & Clinical Psychology
Adolescents; sickle cell disease; transition; chronic pain; migraines; cultural competence
PsyD: Wright State University, Dayton, Ohio, 1995.
Residency: Cincinnati Children's Hospital Medical Center.
Fellowship: Clinical Psychology, INTERACT Behavioral Healthcare Services Inc, Columbus, OH, 1995-1996.
Hines J, Mitchell M, Crosby L, Johnson A, Valenzuela J, Kalinyak K, Joiner C. Engaging Patients with Sickle Cell Disease and their Families in Disease Education, Research, and Community Awareness. J Prevent Intervent Comm. 2011.
Neal-Barnett A, Stadulis M, Payne MR, Crosby L, Mitchell M, Williams L, Costa CW. In the company of my sisters: Sister circles as an anxiety intervention for professional African American women. J Affect Disord. 2011 Mar;129(1-3):213-8.
Oliver-Carpenter G, Barach I, Crosby LE, Valenzuela J, Mitchell MJ. Disease management, coping, and functional disability in pediatric sickle cell disease. J Natl Med Assoc. 2011 Feb;103(2):131-7.
Lynch-Jordan AM, Kashikar-Zuck S, Crosby LE, Lopez WL, Smolyansky BH, Parkins IS, Luzader CP, Hartman A, Guilfoyle SM, Powers SW. Applying quality improvement methods to implement a measurement system for chronic pain-related disability. J Pediatr Psychol. 2010 Jan-Feb;35(1):32-41. Brinkman WB, Sherman SN, Zmitrovich AR, Visscher MO, Crosby LE, Phelan KJ, Donovan EF. Parental angst making and revisiting decisions about treatment of attention-deficit/hyperactivity disorder. Pediatrics. 2009 Aug;124(2):580-9.
Crosby LE, Modi AC, Lemanek KL, Guilfoyle SM, Kalinyak KA, Mitchell MJ. Perceived barriers to clinic appointments for adolescents with sickle cell disease. J Pediatr Hematol Oncol. 2009 Aug;31(8):571-6.
Bolling C, Crosby L, Boles R, Stark L. How pediatricians can improve diet and activity for overweight preschoolers: a qualitative study of parental attitudes. Acad Pediatr. 2009 May-Jun;9(3):172-8.
Modi A, Crosby L, Guilfoyle S, Lemanek K, Witherspoon D, Mitchell M. Barriers to Treatment Adherence for Pediatric Patients with Sickle Cell Disease and their Families. Children’s Health Care. 2009.
Beidel D, Turner S, Sallee R, Ammerman R, Crosby L, Pathak S. SET-C vs. fluoxetine in the Treatment of Childhood Social Phobia. J Am Acad Child Adolesc Psych. 2007;46:1622-1632.
Mitchell MJ, Lemanek K, Palermo TM, Crosby LE, Nichols A, Powers SW. Parent perspectives on pain management, coping, and family functioning in pediatric sickle cell disease. Clin Pediatr (Phila). 2007 May;46(4):311-9.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center